Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means

Pediatric Nephrology

Volumn 20, Issue 3 SPEC. ISS., 2005, Pages 399-403

  Drüeke, Tilman B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Calcimimetics; Calcium supplements; Chronic kidney disease; Dietary phosphate restriction; Phosphate binders; Secondary hyperparathyroidism; Vitamin D derivatives

Indexed keywords

ACETIC ACID; ALFACALCIDOL; BICARBONATE; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SALT; CINACALCET; COLECALCIFEROL; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; VITAMIN D DERIVATIVE;

CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE COURSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EXPERIENCE; GROWTH DISORDER; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; NAUSEA; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PATIENT REFERRAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SECONDARY HYPERPARATHYROIDISM; TIME; TREATMENT PLANNING; VOMITING;

ANIMALS; CHILD; CLINICAL TRIALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 14644392849     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1745-0     Document Type: Review

References (32)

1. Moe SM, Drueke TB (2003) Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23:369-379
2. Eknoyan G, Levin A, Levin NW (2003) Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1-201
3. Lorenzo V, Martin M, Rufino M, Jimenez A, Malo AM, Sanchez E, Hernandez D, Rodriguez M, Torres A (2001) Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 37:1260-1266
4. Cunningham J, Makin H (1997) How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 12:16-18
5. Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55:2169-2177
6. Atik A, Ghazali A, Achard JM, Rida Z, Oprisiu R, Brazier M, Leflon P, Gueris J, Moriniere P, Sari Z, Fournier A (1997) La déplétion relative en vitamine D native: Un facteur de risque potentiel chez l'hémodialysé algérien de lésions radiologiques d'hyperparathyroïdie et d'ostéomalacie indépendant de la calcitriolémie. Nephrologie 18:47-52
7. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456 10.1056/NEJMoa022536
8. Drueke TB, McCarron DA (2003) Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med 349:496-499
9. Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C (1993) Calcium kinetics and the long-term effects of lowering dialysate calcium concentration Kidney Int 43:630-640
10. Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HLJ (1992) Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 7:63-68
11. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E (1997) Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71
12. Slatopolsky EA, Burke SK, Dillon MA (1999) RenaGel (R), a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55:299-307
13. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252 10.1046/j.1523-1755.2002.00434.x
14. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N (2003) Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441-450
15. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661 10.1046/j.1523-1755.2003.00284.x
16. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int [Suppl] S73-S78
17. Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C (1989) Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36:1112-1118
18. Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship THJ (1997) Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 8:627-631
19. Brown EM, Pollak M, Riccardi D, Hebert SC (1994) Cloning and characterization of an extracellular Ca2+-sensing receptor from parathyroid and kidney: New insights into the physiology and pathophysiology of calcium metabolism. Nephrol Dial Transplant 9:1703-1706
20. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644-5649 10.1210/jc.2002-021597
21. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583 1:CAS:528:DC%2BD3sXht1Kjtro%3D
22. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calciumxphosphorus in secondary hyperparathyroidism. Kidney Int 63:248-254
23. Block GA, Martin KJ, deFrancisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) The calcimimetic cincalcet (AMG 073) for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med 350:1516-1525 10.1056/NEJMoa031633
24. Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223-227
25. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445
26. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024 1:CAS:528:DC%2BD38XjtFSntL0%3D
27. Moe SM, Sprague SM, Cunningham J, Drueke TB, Adler S, Rosansky SJ, Albizem MB, Guo MD, Zani V, Goodman WG (2003) Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCl. J Am Soc Nephrol 14:463A
28. Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239-297
29. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N (1998) NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453
30. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983 1:CAS:528:DyaK2sXotVyku7s%3D
31. Martin D, Miller G, Colloton M, Shatzen E, Lacey D (2003) Cincacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic renal insufficiency (CRI). J Am Soc Nephrol 14:462A
32. Ogata H, Ritz E, Odoni G, Amann K, Orth SR (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959-967 1:CAS:528:DC%2BD3sXitF2jtbc%3D